How to Cite
Abstract
Abstract. Disturbance of the intestinal microbiota is one of the key pathophysiological mechanisms in the development of obesity, metabolic syndrome and type 2 diabetes (T2D). Microbial metabolites, in particular short-chain fatty acids (SCFAs), are involved in the pathogenesis of T2D and cardiometabolic complications by modulating pathophysiological processes, such as chronic lowgrade inflammation, oxidative stress (OS), and lipid and glucose dysmetabolism. The search for objective criteria for early clinical and laboratory diagnostics is relevant in order to develop targeted differentiated schemes for the correction of metabolic disorders in T2D, taking into account the morphological and metabolic aspects of the patient’s phenotype.
The aim: to investigate the features of the relationships between the levels of microbial metabolites and hormonal and metabolic disorders in patients with T2D with different phenotypes, taking into account the degree of OS manifestation.
Material and methods. The study included 88 patients with T2D, comparable in age, concomitant therapy, and compensation for diabetes, in whom anthropometric and compositional parameters were assessed, the level of 8-isoprostaglandin F2α (8-iso-PGF2α) in blood serum and the content of SCFAs in coprofiltrate were determined. In a separate group of patients (n=21), an assessment was made of the relationships between the levels of microbial metabolites and hormonal and metabolic disorders in the dynamics of therapy with GLP-1 receptor agonists (GLP-1 ar).
Results. It was established that in parallel with the increase in the obesity degree, percentage of fat, and level of visceral fat, there was a significant increase in the concentration of 8-iso-PGF2α. Inverse correlations were found between body mass index values and SCFAs levels.
Conclusions. The presence of relationships between the indicators characterizing the obesity phenotype in patients with T2D and the OS degree as well as the possible significance of the metabolic activity of the intestinal microbiota in the development of obesity-related dysmetabolic disorders in T2D was confirmed. The use of arGLP-1 may help restore the impaired metabolic activity of the intestinal m
References
Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018 Apr 3;27(4):740-56. doi: 10.1016/j.cmet.2018.03.001.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021 Apr;46:101102. doi: 10.1016/j.molmet.2020.101102.
Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, et al. American Association of Clinical Endocrinology Consensus Statement: comprehensive type 2 diabetes management algorithm – 2023 update. Endocr Pract. 2023 May;29(5):305-40. doi: 10.1016/j.eprac.2023.02.001.
Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol (Lausanne). 2020 Jan 31;11:25. doi: 10.3389/fendo.2020.00025.
van der Hee B, Wells JM. Microbial regulation of host physiology by short-chain fatty acids. Trends Microbiol. 2021 Aug;29(8):700-12. doi: 10.1016/j.tim.2021.02.001.
Rosli NSA, Abd Gani S, Khayat ME, Zaidan UH, Ismail A, Abdul Rahim MBH. Short-chain fatty acids: possible regulators of insulin secretion. Mol Cell Biochem. 2023 Mar; 478(3):517-30. doi: 10.1007/s11010-022-04528-8.
He M, Tan CP, Xu YJ, Liu Y. Gut microbiota-derived trimethylamine-N-oxide: A bridge between dietary fatty acid and cardiovascular disease? Food Res Int. 2020 Dec; 138(Pt B):109812. doi: 10.1016/j.foodres.2020.109812.
Степанова НМ, Дріянська ВЄ, Король ЛВ, Мигаль ЛЯ, Савченко ВС. Вплив індигенної мікробіоти кишківника на інтенсивність оксидативного стресу та цитокінову ланку імунітету в жінок з рецидивуючим пієлонефритом. Медичні перспективи. 2018;23(1/1):129-35 (Stepanova NM, Driyanska VE, Korol LV, Mihal LYa, Savchenko VS. The effects of gut indigenous microbiota on intensity of oxidative stress and the cytokine immunity in women with recurrent pyelonephritis. Med. Perspekt. 2018;23(1/1):129-35. Ukrainian). doi: 10.26641/2307-0404.2018.1(part1).127251.
Кравчун НО, Дорош ОГ, Овсяннiкова ТМ, Алексеєва II. Властивостi 8-iзопростагландину та його взаємозв’язок з оксидативним стресом у хворих на цукровий дiабет 2 типу з неалкогольною жировою хворобою печiнки (огляд лiтератури та власнi дослiдження). Проблеми ендокринної патологiї. 2014; 47(1):63-71 (Kravchun NO, Dorosh OG, Ovsyannikova TM, Alekseeva II. The properties of 8-isoprostaglandin and its relationship with oxidative stress in patients with type 2 diabetes and non-alcoholic fatty liver disease (review and own research). Problem of Endocrine Pathology. 2014;47(1):63-71. Ukrainian). doi: 10.21856/j-PEP.2014.1.08.